SciSparc unit NeuroThera Labs starts Phase IIb Tourette trial site at Hannover Medical School
SPRC•Study design and prior results
The study is designed as a randomized, double-blind, placebo-controlled cross-over trial. The primary endpoint is change in the Yale Global Tic Severity Scale at weeks 12 and 26.
Phase IIa results cited an average 21% tic reduction across participants, supporting progression into the Phase IIb program.
Phase IIb trial site opens in Hannover
SciSparc unit NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110 in adult Tourette syndrome.
SCI-110 combines dronabinol with palmitoylethanolamide in one oral dosage form, targeting tic reduction with fewer side effects.
